Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BAT5906 injection in wet age-related macular degeneration
CTR20200667Phase 2Completed
- Sponsor
- BeiGene
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BAT5906 in exudative macular degeneration, sponsored by BeiGene. Started May 2020; status: completed.
02
Drugs
BAT5906
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20200667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200667.